Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor by Scharner,  J. et al.
Original ArticleDelivery of GalNAc-Conjugated Splice-Switching
ASOs to Non-hepatic Cells through Ectopic
Expression of Asialoglycoprotein Receptor
Juergen Scharner,1 Sabrina Qi,1 Frank Rigo,2 C. Frank Bennett,2 and Adrian R. Krainer1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; 2Ionis Pharmaceuticals, Carlsbad, CA, USAReceived 26 July 2018; accepted 28 February 2019;
https://doi.org/10.1016/j.omtn.2019.02.024.
Correspondence: Adrian R. Krainer, Cold Spring Harbor Laboratory, 1 Bungtown
Road, Cold Spring Harbor, NY 11724, USA.
E-mail: krainer@cshl.eduSplice-switching antisense oligonucleotides (ASOs) are prom-
ising therapeutic tools to target various genetic diseases,
including cancer. However, in vivo delivery of ASOs to ortho-
topic tumors in cancer mouse models or to certain target
tissues remains challenging. A viable solution already in use
is receptor-mediated uptake of ASOs via tissue-speciﬁc recep-
tors. For example, the asialoglycoprotein receptor (ASGP-R)
is exclusively expressed in hepatocytes. Triantennary N-acetyl-
galactosamine (GalNAc) (GN3)-conjugated ASOs bind to the
receptor and are efﬁciently internalized by endocytosis,
enhancing ASO potency in the liver. Here we explore the use
of GalNAc-mediated targeting to deliver therapeutic splice-
switching ASOs to cancer cells that ectopically express ASGP-R,
both in vitro and in tumor mouse models. We found that
ectopic expression of the major isoform ASGP-R1 H1a is sufﬁ-
cient to promote uptake and increase GN3-ASO potency to
various degrees in four of ﬁve tested cancer cells. We show
that cell-type-speciﬁc glycosylation of the receptor does not
affect its activity. In vivo, GN3-conjugated ASOs speciﬁcally
target subcutaneous xenograft tumors that ectopically express
ASGP-R1, and modulate splicing signiﬁcantly more strongly
than unconjugated ASOs. Our work shows that GN3-targeting
is a useful tool for proof-of-principle studies in orthotopic can-
cer models, until endogenous receptors are identiﬁed and
exploited for efﬁciently targeting cancer cells.
INTRODUCTION
Antisense oligonucleotides (ASOs) have become an important thera-
peutic tool that has vastly expanded the types of diseases that can be
treated in a targeted and safe way.1 ASOs are short, chemically modi-
ﬁed, single-stranded oligonucleotides that bind to speciﬁc cRNA
sequences by Watson-Crick base pairing. Based on their design,
they either elicit degradation of the RNA target by RNase H-mediated
cleavage or act as steric blockers of protein or RNP binding, e.g., to
modulate RNA splicing and induce an isoform switch or restore pro-
tein expression.2–4 ASOs have also successfully been deployed to
neutralize microRNAs,5 increase translation,6 and reduce nonsense-
mediated mRNA decay.7 Currently, a major limitation of the use of
ASOs is their efﬁcient delivery to the intended target tissue.8 ASOs
delivered systemically in vivo are cleared rapidly from the blood
and primarily accumulate in the liver and kidney, although ASO pres-Molecular T
This is an open access article under the CC BY-NC-ence and activity have been detected in a wide variety of tissues.9,10
Once ASOs enter cells, they have very long half-lives, ranging from
2–4 weeks in the liver10 to 4–6 months in the CNS.11,12 Antisense
drugs already approved by the US Food and Drug Administration
(FDA) include those designed against diseases affecting tissues that
are either self-contained or easy to target, such as eye, liver, and
CNS.1 An ASO targeting skeletal muscle has also been conditionally
approved by the FDA for Duchenne muscular dystrophy, although its
efﬁcacy is limited by inefﬁcient muscle uptake.13 There are extensive
ongoing efforts to developmethods for efﬁcient, tissue-speciﬁc target-
ing, including aptamers, lipid nanoparticles, cell-penetrating pep-
tides, antibodies, and receptor ligands.8 Tissue-speciﬁc targeting is
especially crucial for cancer therapies, because ASOs are diluted out
in rapidly dividing cells, thus requiring higher and more frequent
dosing, compared with post-mitotic tissues.14,15
A well-established receptor-ligand system to target hepatocytes
already in use in clinical trials is the asialoglycoprotein receptor
(ASGP-R).16 ASGP-Rs are primarily expressed in hepatocytes and
play an important role in clearing glycoproteins from the blood
through clathrin-mediated endocytosis. There are ﬁve receptor iso-
forms encoded by two different genes, ASGR1 and ASGR2. Two
isoforms lack the transmembrane domain and are soluble; the re-
maining three isoforms (ASGP-R1 H1a, ASGP-R H2b, and ASGP-R
H2c) are membrane bound, and homo- and hetero-oligomerize upon
ligand binding on the cell surface, before endocytosis. The ligand
speciﬁcity is determined by the receptor-oligomer composition.17
ASOs conjugated with N-acetylgalactosamine (GalNAc), a natural
ASGP-R ligand, are efﬁciently bound by the receptor and internalized
in hepatocytes; as a result, triantennary GalNAc (GN3)-conjugated
ASOs increase the potency of liver-targeting ASOs in vivo by
10-fold.18 Cancer-speciﬁc receptors, such as the IL-13Ra2 or
EGFRvIII receptors, which are speciﬁcally expressed or ampliﬁed
glioblastomas, are already being tested for targeted therapies using
ligand and aptamers, but are not yet widely available.19–21herapy: Nucleic Acids Vol. 16 June 2019 ª 2019 The Authors. 313
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Ectopic Expression of ASGP-R1 in U87 Cells Increases Efficacy of GN3-SMN-ASO In Vitro
(A) Major andminor transmembrane domain (TM)-containing ASGP-R isoform cDNAswere cloned into retroviral and lentiviral expression vectors as indicated. The lentiviral vector
carries the selection marker puromycin. ASGP-R H2c has a short 18-amino acid deletion in the intracellular domain of the receptor. (B) Western blot confirms expression of major
and minor ASGP-R isoforms in U87 glioblastoma cells. The expression level of H1a is approximately 6-fold higher than the endogenous expression level in HepG2 cells,
normalized to tubulin. H2a and H2b isoforms are detectable when expressed alone, but are stabilized in the presence of H1a. (C) Micrographs of U87 cells expressing
ASGPR-H1a and H2b alone, and in combination. Cells were stained for ASGP-R1 (red), ASGP-R2 (green), and DAPI (blue). Arrowheads indicate non-uniform distribution of
ASGP-R H2b, consistent with ER localization. Scale bar, 50 mm. (D) The SMN ASOs used in this study bind to intron 7 of SMN2 and promote exon 7 inclusion. Full-length SMN2
mRNA was quantified by radioactive RT-PCR; the product was digested with DdeI to separate SMN1 from SMN2 products. (E) U87 cells expressing major and minor ASGP-R
isoforms alone or in combination were incubated with 300 nM unconjugated (SMN-MOE) or GalNAc-conjugated SMN-MOE ASOs (GN3-SMN-MOE) for 5 days by free uptake.
(legend continued on next page)
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system for targeted delivery of GN3-conjugated ASOs to non-hepatic
cancer cell lines, by ectopically expressing ASGP-R. Early work char-
acterizing receptors in mouse ﬁbroblasts, as well as more recent work
in HEK293T cells, showed that ASGP-R is functional when expressed
ectopically.22,23 Furthermore, ASGP-R expression can enhance the
potency of unconjugated ASOs in vitro and in vivo, likely via direct
interaction between the phosphorothioate (PS)-modiﬁed ASO back-
bone and the receptor.23,24 Ectopic expression could therefore be used
for proof-of-principle experiments to test the efﬁcacy of therapeutic
ASOs, both in vitro and in vivo, until endogenous, cancer/tissue-spe-
ciﬁc receptors are identiﬁed. We expressed ASGP-R isoforms in
various human cancer cell lines to identify cell-type-speciﬁc differ-
ences in receptor activity, as well as culture conditions that inﬂuence
cellular ASO uptake. We found that ectopic expression of the major
isoform ASGP-R1 H1a is sufﬁcient to promote uptake and increase
GN3-ASO potency in some, but not all, cancer cells we tested. In vivo,
GN3-conjugated ASOs speciﬁcally targeted subcutaneous xenograft
tumors expressingASGP-R1, and induced signiﬁcantly stronger splice
modulation than unconjugated ASOs. We conclude that GN3-target-
ing is a useful method to test therapeutic ASOs in proof-of-principle
in vivo studies employing orthotopic cancer models.
RESULTS
ASGP-R Promotes GN3-Conjugated ASOUptake and Efficacy in
U87 Cells
GN3-conjugated oligonucleotides (small interfering RNAs [siRNAs]
and gapmer ASOs) have been successfully used to target hepatocytes
in vivo via ASGP-R mediated endocytosis. There is extensive effort in
the ﬁeld to identify new receptors, with the aim to deliver ligand-
conjugated ASOs to other target tissues or tumor cells. Even though
comparable receptor-ligand systems are being developed for other
tissues, we aimed to test whether ectopic expression of ASGP-R in
non-hepatic cells can promote uptake and efﬁcacy of GN3-
conjugated splice-modulating ASOs for proof-of-principle experi-
ments in vitro and in vivo.
Hepatocytes express multiple ASGP-R isoforms encoded by two
genes (ASGR1 and ASGR2), and these isoforms oligomerize on the
cell surface upon ligand binding. Because it was unclear which iso-
forms are required to induce GN3 binding and endocytosis, we
cloned all membrane-bound ASGP-Rs into retroviral and lentiviral
expression vectors, to test them in non-hepatic cells (Figure 1A).
HepG2 hepatocellular carcinoma cells, which served as a control,
express low levels of both ASGP-R1 and ASGP-R2 endogenously
(Figure 1B). In U87 glioblastoma cells, ASGP-R is not expressed.
Western blots show strong expression of isoform H1a only in in-
fected cells (Figure 1B). ASGR2 isoforms are retained in the endo-Representative radiograph shows full-lengthSMN2 (top band) andSMN2D exon 7 (bottom
among themeans in the SMNgroup (p = 0.0055) and theGN3-SMNgroup (p < 0.0001) are
H2c does not improve GN3-SMN-MOE uptake when compared with H1a alone (Student
**p < 0.01. (G) U87 and U87-H1a cells exposed to unconjugated and GN3-conjugated SM
Arrows indicate ASGP-R1-expressing U87 cells, and arrowheads indicate ASGP-R1-negplasmic reticulum (ER) and rapidly degraded when expressed alone
in HEK293 cells.22,23 ASGP-R2 isoforms expressed individually in
U87 cells were not stable and required the presence of isoform
H1a for stability and proper localization, which is consistent with
the literature (Figures 1B and 1C). We conﬁrmed this observation
by immunostaining, which showed accumulation of H2b near the
nucleus (consistent with ER localization) when expressed alone
(Figure 1C, arrowheads).
To test whether ASO uptake and efﬁcacy are improved in ASGP-R-ex-
pressing U87 cells, we used 20-mer unconjugated (SMN-2’-O-
Methoxyethyl [MOE]) and GN3-conjugated (GN3-SMN-MOE) fully
MOE-PS-modiﬁed splice-modulating ASOs. The ASO moiety binds
to an intronic splice silencer site in intron 7 of SMN2, blocking
hnRNPA1 from binding and thereby promoting exon 7 inclusion.25
We measured SMN2 exon 7 inclusion by radioactive RT-PCR with
primers located in exons 6 and 8 (Figure 1D). We delivered ASOs to
control and receptor-expressingU87 cells by free uptake, in the absence
of any transfection reagent, for 5 days at a ﬁnal concentration of
300 nM.Untreatedwild-type and control U87 cells (no-treatment con-
trol [NTC], GFP) expressed 38.1% (±1.5%) and 41.0% (±0.6%) full-
length SMN2, respectively (Figures 1E and 1F). The proportion of
full-length SMN2 mRNA signiﬁcantly increased to a similar extent in
wild-type U87 cells exposed to unconjugated and GN3-conjugated
SMN-ASOs (50.4% ± 0.7% and 47.4% ± 0.4% respectively; Figure 1F).
In U87 cells expressing ASGP-R isoforms H1a, H2b, and H2c alone or
in combination, unconjugated SMN-ASOs induced exon 7 inclusion to
a similar extent as inASO-treated control cells (48.4%–56.5%). The dif-
ferences within the SMN group, despite being relatively small, are sta-
tistically signiﬁcant (p = 0.0055; one-way ANOVA). GN3-conjugated
ASOs, in contrast, performed signiﬁcantly better in ASGP-R1-express-
ing cells. U87-H1a cells expressed 50.9%± 1.0% full-length (FL)-SMN2
when treated with unconjugated SMN-ASOs and 75.3% ± 1.1% FL-
SMN2 when treated with GN3-conjugated SMN-ASOs. In cells ex-
pressing two ASGP-R isoforms (U87-H1a/H2b and U87-H1a/H2c),
the expression of FL-SMN2 was not signiﬁcantly different from that
in U87 cells expressing the H1a isoform alone. This observation sug-
gests that in U87 cells, expression of the ASGP-R H1a isoform is sufﬁ-
cient to induce uptake of GN3-conjugated ASOs. We also tested cells
expressing all threemembrane-bound isoforms and sawno statistically
signiﬁcant improvement over U87-H1a cells (Figure S1).
We conﬁrmed speciﬁc GN3-ASO targeting to U87-H1a cells by
immunohistochemistry. We exposed a mixture of U87-WT (wild-
type) and U87-H1a cells to 300 nM unconjugated or GN3-
conjugated ASO for 24 h, and stained for ASGP-R and ASO, the
latter with an antibody that recognizes the PS backbone. As shown
in Figure 1G, internalization of unconjugated ASOs was inefﬁcientband). (F) Quantification of full-lengthSMN2 in ASO-treatedU87 cells. The differences
statistically significant (one-wayANOVA). However, co-expression of H1awithH2b or
’s t test). n = 3 independent retroviral transductions; bar graphs represent mean ± SE.
N-ASOs for 24 h. Cells were stained for ASGP-R1 (red), ASO (green), and DAPI (blue).
ative cells. Scale bar, 50 mm. n.s., not significant; NTC, no-treatment control.
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ASO staining was much stronger in U87-H1a cells than in
U87-WT cells, demonstrating greatly enhanced uptake efﬁciency.
However, Gn3-ASO staining was detectable in U87-WT cells,
showing that GN3-ASO can be internalized through alternative
pathways, or the GN3-ligand was metabolized releasing the ASO
over the incubation period.
GN3-ASO Uptake Efficiency Correlates with ASGP-R1
Expression Level
ASGP-Rs are among the most highly expressed receptors, although
there is evidence that only a small pool of receptors is required for
efﬁcient ASO internalization.23 To test whether the expression level
positively inﬂuences GN3-ASO activity, we transiently expressed
ASGP-R1 in U87 cells by transduction with increasing retroviral titers
(U87-low/medium/high; Figure 2A) and then treated these cells with
0–30 mM SMN-ASOs in seven-point dose-response experiments for
5 days. Figures 2B and 2C show that the proportion of FL-SMN2
increased with the ASO dose in U87-WT cells. Unconjugated and
GN3-conjugated ASOs had very similar effects in cells lacking
ASGP-R1. However, with increasing levels of ASGP-R1, the potency
of GN3-conjugated ASOs (green curve) increased, compared with un-
conjugated ASOs (black curve). In U87-high cells, the GN3-ligand
increased the ASO potency by approximately 50-fold, compared
with its unconjugated counterpart. In U87-low and U87-medium
cells, the potency of the GN3-conjugated ASOs increased only
approximately 10-fold and 20-fold, respectively (Figure 2C). Interest-
ingly, transient expression of ASGP-R1 in A172 cells, a different
human glioblastoma cell line, resulted in only a 3-fold increase in
potency of the GN3-conjugated ASO, even in cells expressing high
levels of ASGP-R1 (Figure S2). This poor performance of ASGP-R1
in A172 cells, despite high levels of expression of ASGP-R1, suggests
that expression of the receptor is insufﬁcient to enhance activity of the
GN3-conjugated ASO.
In the dose-response experiments described above, we noticed an in-
crease in the baseline expression of FL-SMN2 in U87-high cells,
compared with U87-WT and U87-low cells, which may inﬂuence
ASO potency (Figure 2C). SMN2 splicing was shown to be inﬂuenced
by the pH of the culture medium.26 U87-high cells were less conﬂuent
at the time of the analysis, and the medium pH was higher, likely
because of the lower growth rate, compared with WT cells. We there-
fore looked at the dynamics of SMN2 exon 7 splicing in a time- and
cell-density-dependent manner, and how this dynamic inﬂuences
ASO potency. As expected, exon 7 inclusion decreased markedly
over time in untreated U87-WT cells, and this reduction took place
earlier when the cells were seeded at a 4-fold higher density (Fig-
ure 2D, ASO). U87-WT cells treated with 300 nM SMN-MOE
ASO by free-uptake showed increased exon 7 inclusion, compared
with the untreated control, at all time points (Figure 2D, +ASO).
Furthermore, the effect of the ASO increased with time, likely because
of slow and continuous cellular uptake and endosomal release.
However, the effect of the ASO was also greater in cells seeded at a
higher density, even at the same time point (compare Figure 2D,316 Molecular Therapy: Nucleic Acids Vol. 16 June 2019day 5). This result is intriguing, because in low-density cultures there
are fewer cells competing for the ASO, and the FL-SMN2 baseline is
higher, which should favor ASO-induced exon 7 inclusion. The
observed effect must therefore be caused by intrinsic changes in
U87 cells cultured at a higher density, resulting in increased internal-
ization or endosomal release. Interestingly, we did not observe a
cell-density-dependent effect on the potency of unconjugated SMN-
ASO in HEK293T cells (Figure S2) or A172 cells (data not shown).
Next, we tested whether GN3-mediated delivery of ASO is also
inﬂuenced by cell density. We integrated ASGP-R1 into the genome
of U87 cells by lentiviral transduction to generate a stable cell line,
and exposed low- and high-density cultures to unconjugated and
GN3-conjugated ASOs at a ﬁnal concentration of 0–30 mM for
5 days. Interestingly, the potency of unconjugated ASOs was
15-fold greater in U87-H1a cells grown at high density (Figure 2E).
The potency of GN3-conjugated ASOs, in contrast, was similar in
low- and high-density cultures, with a half-maximal effective
concentration (EC50) of 27 and 17 nM, respectively (1.6-fold
difference).
Ectopic Expression of ASGP-R in HepG2 Cells Increases
GN3-ASO Activity in 3D Culture
ASGP-Rs are naturally expressed in hepatocytes and promote GN3-
mediated ASO-uptake in vivo. In hepatocellular carcinoma (HCC)
cell lines, however, ASGP-R-mediated ASO delivery was reported
to be inefﬁcient, which may be explained by lower receptor levels in
HCC cells.23 When we tested SMN2 exon 7 inclusion in HepG2 cells
exposed to ASOs in the culture medium for 5 days, we found that
unconjugated and GN3-conjugated ASOs performed very similarly
(Figure 3A). To show whether increased receptor expression im-
proves GN3-ASO activity, we established HepG2 cells with stable
expression of ASGP-R1 and ASGP-R2, alone and in combination
(Figure 3B). Interestingly, overexpression of ASGP receptors did
not enhance GN3-ASO activity in HepG2 cells (Figure 2C).
GN3-ASOs did result in a slight increase of FL-SMN2, compared
with unconjugated ASOs, in both WT and ASGP-R-expressing cells
(46.9% ± 5.5% and 53.8% ± 6.7% FL-SMN2 in HepG2-WT, respec-
tively; p = 0.042). However, overexpression of receptors alone or in
combination did not enhance GN3-ASO activity in HepG2 cells (Fig-
ure 3C). Immunostaining of HepG2 cells for the presence of the ASO
in cells exposed to 300 nM ASO for 24 h is consistent with this
ﬁnding: GN3-ASO staining was qualitatively indistinguishable be-
tween HepG2-WT and HepG2-H1a cells (Figure 3D), which is dras-
tically different from the results obtained in U87 cells (compare with
Figure 1G).
HepG2 cells cultured in ultra-low-attachment plates aggregate to
form 3D clusters of cells (Figure 3E) and maintain ASGP-R expres-
sion (Figure 3F). We delivered ASOs to these cultures at a ﬁnal con-
centration of 300 nM by free uptake for 5 days, before analyzing
SMN2 exon 7 inclusion (Figure 3G). In this case, HepG2-H1a cells
treated with GN3-ASO showed slightly higher FL-SMN2 expression
(40.8% FL-SMN2) compared with HepG2-WT (34.8% FL-SMN2)
Figure 2. GN3-ASO Activity Positively Correlates with ASGP-R1 Expression Level
(A) U87 cells were transduced with various titers of ASGP-RH1a retrovirus. Western blot shows increased expression of the ASGP-R1 isoform in U87 cells. (B) Representative
radioactive gels of U87 and U87-H1a-high cells treated with SMN and GN3-SMN ASOs. Top band shows full-length SMN2, and bottom band shows SMN2 D exon 7
(DdeI digested). (C) Dose-response curves of ASO-treated U87 cells expressing increasing levels of ASGP-R1. (D) SMN2 exon 7 inclusion in U87 cells is time and cell density
dependent. The proportion of full-length SMN2 transcript decreases with time and cell density. Exon 7 inclusion of U87 cells treated with 300 nM SMN-ASO increases over
time and in high-density conditions. Representative radioactive gels are shown below the bar chart. n = 3 independent experiments; bars represent mean ± SE.
(E) Radiographs showing SMN2 splicing in low- and high-density U87-H1a cells treated with 0–30 mMSMN andGN3-SMN-ASO for 5 days. (F) Quantification of bands shown
in (E). Calculated EC50 doses are indicated below the graphs.
www.moleculartherapy.organd HepG2-H2b cells (36.5% FL-SMN2). This increase between
HepG2-H1a and HepG2-WT or HepG2-H2b was not statistically
signiﬁcant. However, in cells expressing both ASGP-R isoforms
(H1a and H2b) in combination, GN3-ASOs performed signiﬁcantly
better than in cells expressing ASGP-R1 alone (50.3% ± 1.8% and
40.8% ± 1.7% FL-SMN2, respectively; p = 0.0023). Interestingly,ASGP-R H1a and H2b expressed together in HepG2 cells also
increased the effect of unconjugated SMN-ASOs (p = 0.054, one-
way ANOVA) (Figure 3G). We also saw a modest, but statistically
signiﬁcant difference in the SMN group in U87 cells expressing the
ASGP-Rs (Figure 1F). This type of effect was reported before and is
speciﬁc for PS-modiﬁed ASOs.23,24Molecular Therapy: Nucleic Acids Vol. 16 June 2019 317
Figure 3. Ectopic Expression of ASGP-R in HepG2 Cells Increases GN3-ASO Activity in 3D Culture
(A) Quantification of full-length SMN2mRNA in HepG2 cells treated with 0–30 mMSMN andGN3-SMN-ASO for 5 days. (B)Western blots of stable 2DHepG2 cells expressing
ASGP-R H1a and H2b alone or in combination. Tubulin served as a loading control. (C) Quantification of full-length SMN2mRNA in 2D HepG2 cells treated with 300 nMSMN
and GN3-SMN-ASOs for 5 days. Ectopic expression of ASGP-R1 and/or ASGP-R2 had no effect on ASO efficacy in 2D HepG2 cultures. p values for each group (one-way
ANOVA) are indicated below the graph. (D) HepG2-WT (arrows) and HepG2-H1a cells (arrowheads) were cultured together and exposed to 300 nM SMN and GN3-SMN
ASO for 24 h. Immunofluorescence staining shows ASGP-R1 (red), ASO (green), and nuclei (blue). HepG2-WT cells are ASGP-R1-positive, but the staining is very weak.
Scale bar, 100 mm. (E) Phase-contrast micrographs of HepG2 cells grown attached on standard tissue culture plates (top) or in 3D cultures on ultra-low-attachment plates
(bottom). Scale bars, 500 mM. (F) Western blots of stable 3D HepG2 cells expressing ASGP-R H1a and H2b alone or in combination. Tubulin served as a loading control.
(G) Quantification of full-length SMN2mRNA in 3D HepG2 cells treated with 300 nM SMN and GN3-SMN-ASOs for 5 days. Exon 7 inclusion upon GN3-SMN-ASO treatment
is significantly greater in 3D HepG2 cells overexpressing ASP-R. p values for each group (one-way ANOVA) are indicated below the graph. n = 3 independent experiments;
bar graphs represent mean ± SE. *p < 0.05; **p < 0.01 (Student’s t test). n.s., not significant; NTC, no-treatment control.
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GN3-ASO-Mediated Uptake
Next, we investigated the effects of posttranslational modiﬁcations on
ASGP-R activity. ASGP-R1 protein migrates as several discrete bands
by SDS-PAGE, which are largely non-overlapping when comparing
U87 and HepG2 cells (Figure 4A). When we expressed human
ASGP-R1 in additional cell lines (Huh7, A172, LN308, HT1080,
and 293T cells), we observed a wide variety of bands, even in cells
of similar origin (compare HepG2 and Huh7 hepatic cells and U87
and A172 glioblastoma cells) (Figure 4B). This could potentially
explain why ASGP-R1 performs better in some cell lines than others.
Human ASGP-R1 has two Asn-residues that are glycosylated: N79
and N147.27 We hypothesized that the different bands might repre-
sent ASGP-R protein at various glycosylation stages, either because
of incomplete processing (localized in the ER) or because some cell
types do not express the required glycosyltransferases. To test
whether proteins are alternatively glycosylated, we digested protein
samples with peptide-N-glycosidase F (PNGase F), an endoglycosi-
dase that catalyzes the deglycosylation of most N-linked
glycoproteins.28 ASGP-R1 protein in untreated whole-cell lysates of
U87-H1a and HepG2-H1a cells had different electrophoretic mobil-
ities (Figure 4C). Upon PNGase treatment, all slower-migrating
bands disappeared and coalesced into a single, faster-migrating
band. This result conﬁrms that there are multiple glycosylation states
of each protein, as well as cell-type-speciﬁc glycosylation patterns.
To test whether the glycosylation state affects ASGP-R activity, we
mutated both Asn-residues to Gln, either alone or in combination,
and cloned these glycosylation-deﬁcient mutants into a lentiviral
expression vector to generate stably transduced U87 cell lines (Figures
4D and 4E).Western blotting of U87 cells expressing the Asnmutants
shows multiple bands. Upon deglycosylation with PNGaseF, all pro-
tein species co-migrated as a single band (Figure 4E). Furthermore,
the expression level of the Asn mutant receptors was similar in the
different stable cell lines (Figure 4F). When we tested the effect of
GN3-conjugated ASOs in U87 cells expressing Asn mutant receptor
isoforms, we found that the glycosylation state of the receptor had
very little to no inﬂuence on ASO uptake and activity (Figures 4G
and 4H). At a single 30 nM dose, mutant receptors performed as
well as fully glycosylated, WT ASGP-R1 (Figure 4I). The improved
potency of the N79Q/N147Q double mutant (1.9-fold) was statisti-
cally signiﬁcant (Figure 4H); however, the baseline expression of
FL-SMN2 was also increased in double-mutant cells, which could
potentially contribute to this effect.
GN3-Conjugated ASOs Can Be Delivered to ASGP-R1-
Expressing Tumor Xenografts In Vivo
Tumor xenografts are notoriously difﬁcult to target by antisense ther-
apy.29 A primary goal of this study, therefore, was to bypass the nat-
ural uptake route by ectopically expressing ASGP-R1, and determine
whether ASGP-R1-expressing tumor cells can be speciﬁcally and efﬁ-
ciently targeted by GN3-ASOs in vivo. We used a subcutaneous U87
xenograft model to test receptor-speciﬁc targeting of GN3-ASOs. We
subcutaneously implanted human U87 cells expressing isoform H1aand control cells expressing isoform H2b into immunocompromised
NSG mice, and administered a total of four subcutaneous ASO doses
at 200 mg/kg/week, starting 10 days post-implantation (Figure 5A).
After a 2-week treatment regimen, we harvested tumor, liver, and
kidney tissues to visualize the ASO distribution by immunohisto-
chemistry (IHC) and to measure SMN2 exon 7 inclusion by RT-PCR
(Figures 5B–5E). Saline and an unconjugated random-sequence con-
trol ASO served as negative controls. We stained all the samples with
H&E, which did not reveal obvious abnormalities or signs of toxicity
(Figure S4). U87-H1a and U87-H2b tumor samples processed for
IHC staining conﬁrmed the expression of these two isoforms, respec-
tively (Figure 5B). Mouse liver samples served as a control and natu-
rally express both isoforms.
Sections stained for ASO localization with a phosphorothioate-back-
bone-speciﬁc antibody showed a signal in all ASO-treated samples,
but not in the saline-treated controls. Unconjugated control and
SMN ASOs showed similar signal intensities in U87-H1a and
U87-H2b tumors. GN3-conjugated SMN-ASOs, however, showed
much stronger staining in U87-H1a cells than in U87-H2b cells.
Furthermore, the signal was also stronger than with unconjugated
ASOs, both in U87-H1a tumors and mouse liver, but not in
U87-H2b tumors. In mouse kidney, both unconjugated and GN3-
conjugated ASOs were internalized by proximal convoluted tubules
(Figure S4). We used western blotting to measure ASGP-R expression
in U87 tumors, which was comparable with that in cultured cells (Fig-
ure 5C). The U87-H1a-speciﬁc targeting of GN3-ASOs also
correlated with signiﬁcantly higher SMN2 exon 7 inclusion in
U87-H1a tumors than in U87-H2b tumors (Figures 5D and 5E).
We also tested a different dosing schedule (more frequent injections
and 20% more ASO), which slightly increased FL-SMN2 levels in
U87-H1a tumors (Figure S5). In conclusion, GN3-mediated delivery
can be used to test therapeutic splice-switching ASOs against targets
of interest in non-hepatic cells in vivo, by overexpressing ASGP-R1,
which is advantageous in the case of difﬁcult-to-target disease models,
such as cancer.
DISCUSSION
RNA-targeting antisense drugs have great clinical potential; however,
efﬁcient delivery of ASO to the intended target tissue remains a chal-
lenge in many cases. There is a concerted effort in the ﬁeld to ﬁnd new
ASO formulations, such as lipid nanoparticles or receptor-ligand
pairs, which will allow efﬁcient and tissue-speciﬁc targeting. The
advantages of such an approach are 3-fold: (1) tissue-speciﬁc target-
ing increases the potency of the ASO by increasing its availability
where it engages its therapeutic target; (2) potential sequence-speciﬁc
or chemistry-class off-target effects would be limited to the targeted
tissue; and (3) efﬁcient internalization in the target tissue, together
with long ASO half-life, means that lower and less frequent dosing
would be required, further improving drug safety.
One receptor-ligand system whose clinical importance has already
been demonstrated is ASGP-R. It is expressed in hepatocytes and
forms multimeric units to bind and internalize GN3-conjugatedMolecular Therapy: Nucleic Acids Vol. 16 June 2019 319
Figure 4. ASGP-R1 Glycosylation State Does Not Affect GN3-ASO Efficacy
(A) Western blot of U87 andHepG2 cells overexpressing ASGPR-H1a.Multiple bands with different electrophoretic mobilities are observed for both cell lines, likely because of
variable posttranslational modifications. (B) Ectopic expression of ASGP-R1 in other cell lines also shows that ASGP-Rs are differentially modified in each cell line. (C)
U87-H1a and HepG2-H1a cell lysates were deglycosylated with peptide-N-glycosidase F (PNGase F). ASGP-R1 protein in untreated whole-cell lysates of U87-H1a and
HepG2-H1a cells migrates at different apparent molecular weights. Upon PNGase treatment, all slower-migrating bands disappear and coalesce into a single, faster-
migrating band, suggesting multiple glycosylation states of each protein, as well as cell-type-specific glycosylation patterns. (D) Glycosylation-deficient ASGP-R1 cDNA in
lentiviral expression vectors. Glycosylated asparagines N79 and N147 were mutated to glutamines, either alone or in combination. (E) U87 cells stably expressing glyco-
sylation-deficient ASGP-R1 mutants. Bands of Asn mutant ASGP-R1 migrate faster, consistent with deficient glycosylation. PNGase-F-digested protein bands (deglyco-
sylated) co-migrate, similar to the double mutant. (F) Quantification of protein bands in (E). Bars show fold-change compared with ASGP-R1 wild-type-expressing U87 cells,
normalized to tubulin. (G) Radioactive RT-PCR showing SMN2 splicing in stable U87 cells expressing wild-type and Asn mutant ASGP-R1, treated with 0–30 mM SMN and
GN3-SMN-ASO for 5 d. (H) Quantification and dose-response curves fromdata in (G). (I) Cells were treated with 30 nMSMN-ASO andGN3-SMNASO for 5 days, in triplicates
for statistical analysis. The differences among the means in the NTC, SMN, and GN3-SMN groups are not statistically significant (one-way ANOVA). p values for each group
are indicated below the graph. Bar graphs represent mean ± SE. NTC, no-treatment control.
Molecular Therapy: Nucleic AcidsASOs. Out of all ﬁve membrane-bound isoforms, ASGP-R H1a has
been shown to be required to bind the GN3-ligand.24 However, until
very recently, it was not known whether it acts cooperatively with
ASGP-R2 isoforms.23 Here we conﬁrm that expression of isoform
H1a alone is sufﬁcient to enhance the activity of GN3-conjugated320 Molecular Therapy: Nucleic Acids Vol. 16 June 2019ASOs in multiple cancer cell lines. However, the effects varied mark-
edly in different cell lines and under different culture conditions.
Given that ASGP-R1 protein migrates as multiple apparent-molecu-
lar weight bands that vary across cell lines, we considered that alter-
native posttranslational modiﬁcations may affect receptor activity.
Figure 5. Delivery of GalNAc-Conjugated ASOs to
Tumor Xenografts
(A) Schematic of the tumor xenograft model and ASO
dosing schedule of tumor-bearing NSG mice. A total of
5 106 U87-H2b cells (control) and U87-H1a cells (active
receptor) were subcutaneously implanted into the left and
right flank of adult NSG mice, respectively. Three animals
per group were treated with saline, control ASO, SMN-
ASO, and GN3-SMN-ASO at 200 mg/kg/week, with two
s.c. injections per week. Three days after the last injection,
tumor, liver, and kidney samples were collected and
processed for RNA, protein, and histological analysis. (B)
Representative pictures of IHC analysis of ASGP-R1/2
expression and ASO localization in U87-H2b, U87-H1a,
and liver sections after 2 weeks of ASO treatment. The
rabbit anti-ASO antibody (Ionis Pharmaceuticals) recog-
nizes the ASO’s phosphorothioate backbone. Scale bar,
100 mm. (C) Western blot analysis of U87-H1a and
U87-H2b tumors confirms ASGP-R1 and ASGP-R2
expression. Cultured U87 cells expressing ASGP-R1 and
ASGP-R2 express comparable receptor levels. (D) SMN2
exon 7 inclusion ratio in saline- and ASO-treated U87-H1
and U87-H2 control tumors was quantified by radioactive
RT-PCR. (E) Quantification of results in (C). n = 3 animals/
treatment; bar graphs represent mean ± SE. *p < 0.05;
**p < 0.01 (Student’s t test). n.s., not significant.
www.moleculartherapy.orgASGP-Rs are glycosylated, phosphorylated, and fatty-acylated, and
receptors on the cell surface are mostly hypophosphorylated and hy-
perglycosylated.30 However, we found that mutating ASGP-R1 glyco-
sylation sites had little to no effect on its activity in U87 cells. We also
observed greater uptake of GN3-conjugated ASOs in HepG2 cells
cultured in 3D compared with 2D, but saw no difference in ASGP-R
glycosylation, supporting this ﬁnding. We cannot rule out an effect of
the phosphorylation state of the receptor, which we did not test in this
study. In addition to alternative posttranslational modiﬁcations
affecting receptor activity in different cell lines or culture conditions,
there are other potential explanations for the observed differences inMolecular TGN3-ASO activity. For example, cells grown in
3D organoids show altered cell polarization
and response to stimuli when compared with
cells grown on a ﬂat surface.31 HepG2 cells
have been shown to undergo a transition from
epithelial to mesenchymal phenotype, which is
accompanied with gene expression changes of
several surface markers when cultured in 3D.32
Cell- and/or tissue-speciﬁc gene expression
levels of factors involved in the endosomal
release pathway may also inﬂuence variability
of GN3-ASO potency in different cell lines.
For example, annexin A2 facilitates transport
of PS-ASOs from early endosomes to late endo-
somes, and is involved in the release of ASOs
from late endosomal compartments.33 Recently,
factors involved in the early endosomal pathway
(Rab5C and EEA1) have also been described tofacilitate endosomal escape of PS-ASOs.34 Expression of all three
factors varies across different tissues and cell types (http://www.
proteinatlas.org/).35
In addition to enhancing GN3-ASO uptake, ASGP-R has also been
reported to increase the effect of unconjugated p = S-modiﬁed
ASOs in vitro and in vivo, albeit to a much lower extent than with
GN3-ASOs.23 In contrast with these studies, our results did not reveal
a measurable impact of ASGP-R1 expression on SMN-ASO activity in
A172, HEK293T, and HT1080 cells. However, we did see a small
increase in activity in HepG2 and U87 cells, but only when bothherapy: Nucleic Acids Vol. 16 June 2019 321
Molecular Therapy: Nucleic AcidsASGP-R H1a and H2b were expressed together. ASOs used in previ-
ous reports were gapmers with several unmodiﬁed DNA bases,
whereas the SMN-ASOs used in the present study were uniformly
MOE-modiﬁed, which could account for the discrepancy.
Another possible explanation for the above discrepancy is the dura-
tion of treatment. Cells treated with gapmer ASOs are frequently
analyzed after a 24-h exposure to the ASO, versus a 5-day exposure
in the case of SMN splice-modulating ASOs. The different time
courses reﬂect in part the destruction of RNA in the case of gapmers,
versus the gradual change in the proportion of two isoforms in the
case of splice-modulating ASOs. GN3-ASOs are internalized rapidly,
as shown here and by others. However, time-course experiments with
SMN-ASOs show a gradual increase in SMN2 exon 7 inclusion over a
5-day treatment period in different cell lines, likely due in part to slow
endosomal release becoming a limiting factor in ASO delivery. As-
sessing splice-modulating ASO activity over time is difﬁcult, because
endogenous SMN2 splicing is very dynamic in cell culture and is cell
type speciﬁc. For example, in untreated U87 cells, FL-SMN2 decreases
over time; in HEK293T cells, FL-SMN2 levels go up; and in A172
cells, SMN2 splicing remains largely unchanged. SMN2 splicing is
inﬂuenced by altered expression of splicing factors, which is regulated
by environmental factors, such as the pH of the medium.26
Perhaps the most unexpected result in this study is that the activity of
unconjugated ASOs was heavily inﬂuenced by cell density in U87
cells. Unconjugated SMN-ASOs were 15-fold more potent in high-
density cultures than in low-density cultures after a 5-day treatment
period. The ASO phosphorothioate backbone has been shown to bind
proteins, which may facilitate ASO internalization via unknown re-
ceptors.36 Environmental changes in high-density U87 cultures,
such as lower medium pH, faster growth-factor depletion, and
increased cell-cell contacts, may result in expression or conforma-
tional changes of unidentiﬁed cell-surface receptors required for
ASO uptake. Alternatively, environmental and/or physiological
changes may also affect endosomal release or intracellular ASO traf-
ﬁcking. However, this latter explanation seems less likely, because
ASO delivery via ASGP-R did not appear to be affected by cell density,
showing more consistent dose-dependent SMN2 exon 7 inclusion.
The growth conditions of cancer cells in tumor mouse models are
very different from cell culture conditions. In addition to cellular up-
take itself, ASO delivery to cancer cells in vivo is also inﬂuenced by
plasma concentration and tumor vascularization. Furthermore, WT
and ASGP-R-expressing tumor cells compete with other cell types,
including hepatocytes, which take up and clear ASOs rapidly. Suc-
cessful delivery of unconjugated and GN3-conjugated ASOs to cancer
cells was therefore not guaranteed. Consistent with this assumption,
FL-SMN levels increased only marginally in unconjugated ASO-
treated tumors, even at doses far above those required to correct
SMN2 splicing in the CNS or in hepatocytes of SMN2-transgenic
mice. GN3-conjugated ASOs, in contrast, were efﬁciently targeted
to ASGP-R-expressing cancer cells, resulting in robust splice-
switching in vivo.322 Molecular Therapy: Nucleic Acids Vol. 16 June 2019Another potential application of the receptor-ligand system could be
to ectopically express ASGP-R in speciﬁc tissues by lentiviral trans-
duction or transplantation of ASGP-R-expressing stem cells. For
example, one could use receptor-expressing muscle satellite cells to
target ASOs speciﬁcally to regenerating muscle, or express ASGP-R
in a subpopulation of cells in the CNS with a viral vector, followed
by ASO treatment. This would not only allow testing of therapeutic
ASOs, but could also serve to generate a disease phenotype associated
with a splicing defect in a speciﬁc cell population, expanding the
molecular toolbox to study splicing in health and disease.37
In conclusion, our work shows that GN3-mediated targeting of ASOs,
combined with ectopic ASGP-R expression, is an effective tool for
proof-of-principle studies to test novel ASO-mediated splice-
switching therapies, until more efﬁcient and speciﬁc targeting
methods become available.
MATERIALS AND METHODS
Animals and Tumor Model
Non-obese diabetic-severe combined immunodeﬁciency (NOD-
SCID)-gamma (NSG) immunocompromised mice (strain 005557;
The Jackson Laboratory) were housed in vented cages and bred in-
house. U87 tumor xenografts were established by injecting 5  106
U87 cells (50,000 cells/mL in Hank’s balanced salt solution [HBSS])
subcutaneously into the ﬂanks of adult NSG mice. Once tumors
were palpable (7–10 days post-transplantation), animals were
treated with ASOs delivered by subcutaneous (s.c.) injection at
200–250 mg/kg/week, with two to ﬁve injections per week. All animal
protocols were performed in accordance with Cold Spring Harbor
Laboratory’s Institutional Animal Care and Use Committee (IACUC)
guidelines.
Plasmids
Full-length human ASGR1-H1a (GenBank: NM_001197216.2),
ASGR2-H2b (GenBank: NM_001201352.1), and H2c (GenBank:
NM_080913.3) cDNA sequences were ampliﬁed from HepG2 cDNA
samples and cloned into a pMSCV retroviral backbone38 by conven-
tional cloning and into a lentiviral backbone containing a
puromycin selection marker (kindly provided by Scott Lyons, CSHL)
using Gibson Assembly cloning (NEB, Ipswich, MA, USA). Retrovi-
ruses and lentiviruses were produced inHEK293T/17 cells by co-trans-
fecting viral constructs with psPAX2 and vesicular stromatitis virus G
glycoprotein (VSVG). Viral supernatant was collected 48–72 h post-
transfection, ﬁltered, and stored at80C. To generate stable cell lines,
U87 andHepG2 target cells were infected with lentiviral particles over-
night, in the presence of 8 mg/mL polybrene (Sigma, St. Louis, MO,
USA), and selected using 1–2 mg/mL puromycin (Sigma, St. Louis,
MO, USA) for at least 2 weeks. Cell lines expressing both ASGP-R
H1a and H2b isoforms were transduced individually on 2 consecutive
days. Retroviral particles were used only for transient experiments.
Cell Culture
U87 MG, A172, and LN308 glioblastoma cells, Huh-7 HCC cells,
HT1080 ﬁbrosarcoma cells, and HEK293T/17 cells were maintained
Table 1. Antisense Oligonucleotides Used in This Study
Name Ionis No. Length Sequence 50–30 Chemistry
Control MOE 742116 18 nt GCTGATCCGAGTAAGCTC uniform MOE
SMN 387954 20 nt ATTCACTTTCATAATGCTGG uniform MOE
GN3-SMN 699819 20 nt ATTCACTTTCATAATGCTGG 50-GalNAc3-uniform MOE
All ASOs have a uniform PS-backbone and 5-methyl-C modiﬁcation.
www.moleculartherapy.orgin DMEM (Corning, Manassas, VA, USA), supplemented with 10%
fetal bovine serum (FBS; Seradigm VWR, Radnor, PA, USA) and
1% penicillin and streptomycin. HepG2 HCC cells were maintained
in Eagle’s minimal essential medium (EMEM; ATCC, Manassas,
VA, USA), supplemented with 10% FBS and 1% penicillin and strep-
tomycin at 37C/5% CO2. 3D cultures were induced by seeding cells
in ultra-low-attachment plates (Corning, Kennebunk, ME, USA).
Antisense Oligonucleotides
All ASOs used were uniformly modiﬁed withMOE sugars, phosphor-
othioate backbone, and 50-methyl cytosine, and are listed in Table 1.
MOE synthesis, puriﬁcation, and quantiﬁcation were done as
described previously.39 GalNAc-conjugated ASOs were synthesized,
puriﬁed, and quantiﬁed as described previously.18 The GalNAc
moiety was conjugated to the 50 end of the ASO with a trishexylamino
(THA)-C6 cluster. All ASOs were dissolved in water and stored at
20C. ASOs at concentrations ranging from 0.3 nM to 30 mM
were delivered by free uptake for 1–5 days in vitro.
PCR
RNA was extracted from cells and tissue using TRIzol reagent (Invi-
trogen, Carlsbad, CA, USA) and reverse-transcribed using ImProm-II
reverse transcriptase (Promega, Madison, WI, USA). PCR was
performed with AmpliTaq polymerase (Thermo Fisher, Foster
City, CA, USA) using human SMN-speciﬁc exon 6 Fwd 50-
ATAATTCCCCCACCACCTCCC-30 and exon 8 Rev 50-TTGCCA
CATACGCCTCACATAC-30 primers at a ﬁnal concentration of
250 nM. [a-32P]-dCTP radiolabeled PCR products were digested
with DdeI (NEB, Ipswich, MA, USA) for 2 h at 37C and separated
on a 5% native polyacrylamide gel (Bio-Rad, Hercules, CA, USA),
analyzed on a Typhoon 9410 phosphorimager (GE Healthcare),
and quantiﬁed using Multi Gauge v2.3 (Fujiﬁlm, Tokyo, Japan).
The radioactive signal from each band was normalized to the G/C
content to calculate relative changes in splice isoforms.
Western Blotting
Cells and tissues were harvested, lysed in radioimmunoprecipitation
assay (RIPA) buffer supplemented with 1 complete protease inhib-
itor cocktail (Roche, Indianapolis, IN, USA), and sonicated for 10 s
(1 s on/1 s off). The protein concentration of the soluble fraction
was determined by Bradford assay (Bio-Rad, Hercules, CA, USA)
before adding Laemmli loading buffer. To assay the protein glycosyl-
ation state, the soluble fraction was denatured and treated with
PNGase F (P0809; NEB, Ipswich, MA, USA) for 1 h at 37C, accord-
ing to the manufacturer’s instructions, before adding Laemmliloading buffer. Protein lysates were separated on denaturing poly-
acrylamide gels, transferred onto nitrocellulose membranes, and
blocked with 5% milk in TBST (Tris buffered saline, 0.1% Tween 20).
Membranes were incubated overnight at 4C with blocking buffer
containing primary antibodies rb-ASGP-R1 (1:6,000; 11739-1-AP;
ProteinTech), rb-ASGP-R2 (1:3,000; ab200196; Abcam, Cambridge,
UK), and ms-a-tubulin (1:10,000; T9026; Sigma). After incubating
the membranes with goat anti-mouse and goat anti-rabbit Li-Cor
IRDye 800 (green) and 680 (red) secondary antibodies (1:10,000;
Li-Cor, Lincoln, NE, USA) in blocking buffer for 1 h at room temper-
ature, protein bands were visualized on an Odyssey imaging system
(Li-Cor, Lincoln, NE, USA) and analyzed using ImageStudio and
ImageJ. EZ-Run pre-stained markers (Fisher Scientiﬁc, Hampton,
NH, USA) or Precision Plus Protein Dual Color Standards (Bio-
Rad, Hercules, CA, USA) served as molecular weight markers.
Immunofluorescence
Cells were seeded onto eight-well culture slides (Falcon, Big Flats, NY,
USA), ﬁxed with 4% PFA/PBS, and permeabilized with 0.5% Triton
X-100/PBS. Samples were blocked with 10% normal goat serum
(NGS; Invitrogen, Rockford, IL, USA) and 2% BSA in TBST for 1 h
at room temperature, and incubated with primary antibodies
ms-ASGP-R1 (1:1,000, MAB4394; Novus Biologicals), rb-ASGP-R2
(1:500, ab200196; Abcam), and rb-ASO (1:1,000; Ionis Pharmaceuti-
cals) in TBST supplemented with 2% NGS and 2% BSA at 4C over-
night. Secondary antibodies used were Alexa Fluor 488 (green) and
594 (red) (1:500; Invitrogen, Eugene, OR, USA), and nuclei were
stained with DAPI. Pictures were captured on a Zeiss Observer
microscope. All images within the same ﬁgure panel were taken
with the same exposure settings and identically processed using Zeiss
Zen software and Adobe Photoshop.
IHC
Tissue samples were ﬁxed in 4% PFA/PBS (EMS, Hatﬁeld, PA, USA)
and parafﬁn embedded. Six-micrometer sections were deparafﬁnized
and rehydrated. Endogenous peroxidase was blocked in H2O2/meth-
anol for 15 min. Slides were then boiled in 10 mM sodium citrate,
0.05% Tween 20 for 5 min under pressure (for protein antigens), or
treated with Proteinase K (Dako, Carpinteria, CA, USA) for 8 min
to unmask epitopes (for ASO staining). Slides were blocked for
30 min with peptide blocking solution (Innovex Biosciences, Rich-
mond, CA, USA) and incubated with the following primary
antibodies for 1 h at room temperature: rb-ASGP-R1 (1:500,
11739-1-AP; ProteinTech), rb-ASGP-R2 (1:600, ab200196; Abcam,
Cambridge, UK), and rb-ASO (1:10,000; Ionis Pharmaceuticals).Molecular Therapy: Nucleic Acids Vol. 16 June 2019 323
Molecular Therapy: Nucleic AcidsThe signal was visualized with horseradish peroxidase (HRP)-labeled
anti-rabbit polymer (DAKO, Carpinteria, CA, USA) and DAB
(DAKO, Carpinteria, CA, USA). Slides were counterstained with
hematoxylin (Sigma, St. Louis, MO, USA) and mounted with
Limonene mounting medium (Abcam, Cambridge, UK).
Statistics and Graph Representation
One-way ANOVA was used to test for statistical differences among
the means of groups. p values <0.05 were considered statistically sig-
niﬁcant. For pairwise analysis and to answer speciﬁc questions, we
used paired Student’s t test to test statistical difference. EC50 values
were determined by ﬁtting a sigmoidal dose-response curve (variable
slope) to the data, with bottom and top limits set toR0% and%100%
full-length SMN2, respectively. Graphs were generated using
GraphPad Prism and Microsoft Excel. Figures were compiled using
Adobe Photoshop and Adobe Illustrator.
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